A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms MAGELLAN-2
- Sponsors AbbVie
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Planned number of patients changed from 90 to 100.
- 20 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History